Stitch Fix, Inc. (Nasdaq: SFIX), an online personal styling service, reported a third-quarter fiscal 2023 loss of $0.19 per share, beating the consensus estimate of a loss of $0.30 per share. The company also exceeded its adjusted EBITDA guidance by delivering $10.1 million, leading to a significant expansion of its free cash flow. 

Looking ahead to the fourth quarter of fiscal 2023, Stitch Fix expecs net revenue in the range of $365 million to $375 million, slightly below the consensus estimate of $379.41 million. 

In after-hours, $SFIX was trading at $3.84, reflecting a positive movement of $0.16 (+4.34%).

LianBio (Nasdaq: LIAN), a biopharmaceutical company, recently announced positive topline results from a Phase 2a proof of concept trial evaluating infigratinib in Chinese patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma, specifically targeting fibroblast growth factor receptor-2 (FGFR2) gene amplification. 

The trial data suggest that infigratinib has the potential to offer meaningful clinical benefits in third-line or later gastric cancer. As a result, the China National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation to infigratinib for the treatment of gastric cancer, aiming to expedite its development and review process. 

Following this announcement, $LIAN was trading at $2.76, up $0.20 (+7.81%) in after-hours.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)